Analytic Partners Placed Highest for Ability to Execute and Furthest for Completeness of Vision MIAMI , Nov. 22, 2024 /PRNewswire/ -- Analytic Partners, the Commercial Intelligence company for insights-driven brands, today announced it has been recognized as a Leader in the inaugural Gartner® Magic QuadrantTM for Marketing Mix Modeling (MMM) Solutions. Analytic Partners is positioned highest in Ability to Execute and furthest in Completeness of Vision. "We believe our position as a Leader underscores our dedication to our customers and our ongoing commitment to innovation," said Nancy Smith , President and CEO of Analytic Partners. "We appreciate the extensive research Gartner has done in guiding our industry forward. This recognition, we feel, highlights the critical role Commercial Analytics plays in delivering forward-looking decisioning for lasting, meaningful growth." Elevating Insights Beyond MMM and MTA Analytic Partners' longstanding commitment to deliver insights and solutions extends well beyond Multi-Touch Attribution (MTA) and MMM. Analytic Partners' Commercial Analytics solution integrates all factors driving performance outcomes – including finance, supply chain and other enterprise functions. This holistic, company-wide approach provides a forward-looking decisioning framework that brands rely on to measure both short-term and long-term impact, ensuring sustained growth. GPS Enterprise: A Powerful Platform for Enabling Growth Powered by the GPS Enterprise platform, Commercial Analytics combines data science and technology to deliver actionable insights that enable brands to make proactive, forward-looking commercial decisions. This end-to-end platform, informed by ROI Genome intelligence, ensures streamlined data management, application of advanced analytics and multi-objective optimizations to help brands meet their growth goals. Recognition extends to Gartner Critical Capabilities Report for MMM Solutions The recognition also extends beyond the Magic QuadrantTM. In the accompanying Critical Capabilities report for MMM Solutions, Analytic Partners received the highest scores across all 8 Use Cases, including: Magic Quadrant reports are a culmination of rigorous, fact-based research in specific markets, providing a wide-angle view of the relative positions of the providers in markets where growth is high, and provider differentiation is distinct. Providers are positioned into four quadrants: Leaders, Challengers, Visionaries and Niche Players. The research enables businesses to get the most from market analysis in alignment with your unique business and technology needs. To read the full Magic QuadrantTM report, access a complimentary copy here . Gartner, Magic Quadrant for Marketing Mix Modeling Solutions, Matt Wakeman , David Walters , Joseph Enever , Weicong Zhao , November 19, 2024 GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, Magic Quadrant is a registered trademark of Gartner, Inc. and/or its affiliates and is used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's Research & Advisory organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. About Analytic Partners Analytic Partners is the leader in Commercial Analytics, providing adaptive solutions for deeper business understanding, right-time planning and optimization for marketing and beyond. We turn data into expertise so our customers can create powerful connections with their customers and achieve commercial success. For more information, visit analyticpartners.com . Photo - https://mma.prnewswire.com/media/2565668/Analytic_Partners.jpg View original content to download multimedia: https://www.prnewswire.com/news-releases/analytic-partners-recognized-as-a-leader-in-inaugural-gartner-magic-quadrant-for-marketing-mix-modeling-solutions-302314467.html SOURCE Analytic Partners
AP Trending SummaryBrief at 6:42 p.m. ESTPHILADELPHIA (AP) — The Philadelphia Phillies and right-handed pitcher Joe Ross finalized a one-year contract on Monday. The 31-year-old Ross made 10 starts and 25 total appearances for the Milwaukee Brewers last season. He went 3-6 with a 3.77 ERA. Selected by the San Diego Padres in the first round of the 2011 amateur draft, the 6-foot-4 Ross has pitched in 123 career games across seven seasons with the Washington Nationals and Brewers. In his career, he has combined for a 4.19 ERA with 469 strikeouts to 170 walks. He's 29-34 with a 4.19 career ERA. Ross is the latest in an offseason of minor moves for the NL East champs. The Phillies acquired left-hander Jesús Luzardo from the Miami Marlins and signed free-agent outfielder Max Kepler to a $10 million, one-year deal. AP MLB: https://apnews.com/hub/MLB Copyright 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission. Get local news delivered to your inbox!
As the countdown to the release date begins, excitement is building among fans who have been eagerly awaiting the next chapter in the "Final Destination" saga. With its signature blend of suspense, thrills, and dark humor, "Death Is Coming 6" is shaping up to be a fitting tribute to 25 years of cinematic scares and supernatural mayhem.In conclusion, the Chinese economy in November has showcased resilience, innovation, restructuring, and challenges. As the country continues to navigate through a complex economic landscape, policymakers will need to strike a balance between supporting growth and addressing risks to ensure sustainable development in the future. By leveraging technology, promoting structural reforms, and managing potential risks effectively, China can maintain its economic momentum and achieve long-term prosperity.
Historically, Gu Oju has been a treasured art form in Chinese culture, combining intricate puppetry techniques with storytelling and traditional music. Its unique blend of performance elements has captivated audiences for centuries, making it a beloved form of entertainment. However, in the age of digital media and rapidly changing consumer preferences, Gu Oju has faced challenges in adapting to the modern landscape.
With rookie QB Penix showing poise in starting debut, the Falcons again control their playoff hopes
Dublin, Dec. 17, 2024 (GLOBE NEWSWIRE) -- The "Contract Research Organization (CRO) Services Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F" report has been added to ResearchAndMarkets.com's offering. The Contract Research Organization (CRO) Services Market was valued at USD 81.23 Billion in 2023, and is expected to reach USD 139.42 Billion by 2029, rising at a CAGR of 9.42%. The CRO Services Market is witnessing steady growth driven by the rising complexity and costs associated with in-house drug development processes. Pharmaceutical and biotechnology companies increasingly rely on CROs to outsource their research and development (R&D) activities, benefiting from specialized expertise and cost efficiency. With a robust pipeline of innovative drugs and biologics, there is a growing demand for comprehensive clinical trials and early-phase development services. The increasing focus on precision medicine, personalized therapies, and rare disease research has further amplified the demand for specialized CRO services. Moreover, advancements in technology, such as the integration of artificial intelligence (AI) and machine learning, are enhancing the efficiency and accuracy of clinical trial processes, driving market expansion. The market is characterized by emerging trends such as the adoption of decentralized clinical trials and the incorporation of real-world evidence (RWE) studies to improve trial outcomes. The growing acceptance of hybrid trial models, which combine traditional and virtual methodologies, reflects the industry's evolution toward patient-centric approaches. CROs are also investing heavily in data analytics and AI-based tools to optimize trial designs, enhance patient recruitment, and improve data management. These innovations align with the increasing regulatory requirements for faster drug approval processes, making CROs indispensable partners for pharmaceutical companies. Opportunities abound in the growing biologics and biosimilar segments, as well as in cell and gene therapies, which demand sophisticated R&D and regulatory expertise. Despite significant growth prospects, the market faces several challenges, including regulatory complexities across various regions and ethical concerns in clinical trials. Recruiting and retaining skilled professionals remain a persistent issue, given the high demand for expertise in niche therapeutic areas. Intense competition among CROs and the pressure to deliver cost-effective yet high-quality services further strain the industry. Data privacy concerns and the secure handling of sensitive clinical information also present hurdles, particularly as digitalization becomes more prevalent in clinical research. Addressing these challenges while keeping pace with technological advancements will be critical for sustaining market growth and ensuring reliable service delivery. Key Market Trends Increased Adoption of Decentralized and Virtual Trials The increased adoption of decentralized and virtual clinical trials is a prominent trend driving the global Contract Research Organization (CRO) services market. Decentralized trials (DCTs) use digital technologies to conduct clinical studies remotely, allowing patients to participate from home or local healthcare facilities. This shift is particularly appealing for studies involving chronic conditions, rare diseases, or diverse patient populations spread across vast geographies. Virtual trials enhance patient access and convenience, reduce trial costs, and improve patient retention rates. The rise of telemedicine, wearable devices, and mobile health technologies has made decentralized trials more feasible, offering real-time data collection and monitoring without the need for patients to visit clinical sites. These innovations also address patient concerns related to travel, time commitment, and geographical barriers, which often deter participation in traditional trials. CROs are increasingly adopting DCT models to streamline data collection and improve overall trial efficiency. Additionally, the integration of telehealth services into virtual trials allows for continuous patient engagement, further enhancing the flexibility and scalability of clinical research. The COVID-19 pandemic accelerated the adoption of virtual trials, forcing pharmaceutical companies to adopt remote methodologies to maintain progress in drug development. As the benefits of decentralized trials become more apparent - such as reduced overhead costs, improved data quality, and faster recruitment, many organizations are committing to these models even post-pandemic. This shift is not only changing how trials are conducted but also influencing how CROs design and execute clinical studies, positioning them as essential partners in managing and optimizing the new clinical trial landscape. As DCTs become more commonplace, the demand for CRO services that can manage these trials is expected to increase significantly. Real-World Evidence (RWE) and Real-World Data (RWD) Integration Real-World Evidence (RWE) and Real-World Data (RWD) integration is rapidly transforming the global Contract Research Organization (CRO) services market. These data types are derived from sources outside traditional randomized controlled trials, such as electronic health records (EHRs), insurance claims data, patient registries, and mobile health applications. The growing reliance on RWE and RWD reflects a shift towards more comprehensive, patient-centered approaches in clinical research. Pharmaceutical companies and healthcare providers are increasingly utilizing RWE and RWD to enhance the understanding of how drugs perform in real-world settings, which is essential for regulatory submissions, post-market surveillance, and value-based healthcare models. CROs are playing a crucial role in the integration of RWE and RWD by providing services that capture and analyze these data sources. By incorporating RWD into clinical trials, CROs are helping drug developers evaluate the effectiveness, safety, and long-term outcomes of treatments in broader patient populations. This approach also helps identify treatment patterns, assess the economic impact of therapies, and determine patient subgroups that may benefit the most from certain interventions. Regulatory bodies like the U.S. FDA and EMA are increasingly accepting RWE for drug approval and reimbursement decisions, further propelling its integration into clinical development programs. CROs with expertise in data analytics, biometrics, and regulatory affairs are essential for leveraging the power of RWE and RWD. As these data sources become more critical to drug development, the demand for CRO services that specialize in RWE and RWD integration is expected to grow. The trend supports more informed decision-making, enhances the quality of clinical trials, and accelerates drug approval processes, making CROs indispensable in the evolving pharmaceutical landscape. Regional Insights In 2023, North America emerged as the dominant region in the Global Contract Research Organization (CRO) Services Market, holding the largest market share. Several factors contributed to North America's strong position in the CRO market. The region's advanced healthcare infrastructure, coupled with a robust pharmaceutical and biotechnology sector, has created a favorable environment for clinical research activities. Major pharmaceutical companies and emerging biotech firms in the U.S. and Canada are increasingly outsourcing research and development services to CROs to streamline operations, reduce costs, and accelerate the time to market for new drugs. North America's dominance is also fueled by the region's high R&D investments and the growing number of clinical trials conducted by pharmaceutical companies. With large-scale drug development projects, including clinical trials in oncology, neurology, and immunology, CROs are essential in providing specialized expertise and infrastructure. The region's regulatory bodies, such as the FDA, have also fostered a favorable regulatory environment for clinical research, encouraging both local and global companies to base their clinical trials in North America. Key Market Players Medpace Laboratory Corporation of America ICON IQVIA Syneos Health Parexel Charles River Laboratories International Thermofisher Scientific Pharmaron Beijing Altasciences Key Attributes: Report Scope: In this report, the Global Contract Research Organization (CRO) Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: Contract Research Organization (CRO) Services Market, By Type: Early Phase Development Services Clinical Laboratory Service Others Contract Research Organization (CRO) Services Market, By Application: Oncology Neurology Cardiology Infectious Disease Metabolic Disorder Renal/Nephrology Others Contract Research Organization (CRO) Services Market, By End User: Pharmaceutical & Biotechnological Companies Medical Device Companies Academic & Research Institutes Others For more information about this report visit https://www.researchandmarkets.com/r/5q2t7b About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Contract Research Organization (CRO) Services MarketThe TOI Sports Desk excels in a myriad of roles that capture the essence of live sporting events and deliver compelling content to readers worldwide. From running live blogs for India and non-India cricket matches to global spectacles featuring Indian talents, like the Chess World Cup final featuring Praggnanandhaa and the Badminton World Championships semifinal featuring HS Prannoy, our live coverage extends to all mega sporting events. We extensively cover events like the Olympics, Asian Games, Cricket World Cups, FIFA World Cups, and more. The desk is also adept at writing comprehensive match reports and insightful post-match commentary, complemented by stats-based articles that provide an in-depth analysis of player performances and team dynamics. We track news wires for key stories, conduct exclusive player interviews in both text and video formats, and file content from print editions and reporters. We keep track of all viral stories, trending topics and produce our own copies on the subjects. We deliver accurate, engaging, and up-to-the-minute sports content, round the clock. Read More 2nd Test: India beat Bangladesh by seven wickets to sweep series 2nd Test, Day 4: India push for victory with T20-style batting 2nd Test, Day 1: B'desh 107/3 vs India on rain-shortened opening day Ashwin shines as India hammer Bangladesh in Chennai Test 1st Test, Day 3: India hold upper hand despite spirited Bangladesh chase 1st Test, Day 2: India in box seat after Bumrah takes four-for vs B'desh 1st Test, Day 1: Ashwin, Jadeja dig India out of trouble vs B'desh France waves farewell to Paralympics with spectacular ceremony Navdeep's gold, Simran's bronze take India's medal tally to 29 Paris Paralympics: India's flag bearers for closing ceremony